{"transactions":[{"id":930966,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-26T07:00:09.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":true,"shares":220000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The vesting commencement date is January 1, 2026.  The stock option vests in 48 substantially equal monthly installments.  Accordingly, 1/48th of this stock option vests on February 1, 2026, and monthly thereafter."}],"balance_after":220000,"derivative":{"exercise_price":1.26,"expiration_date":"2036-01-22","underlying":"Common Stock","underlying_shares":220000},"source":{"system":"sec-edgar","filing":"0001193125-26-021658","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000119312526021658/ownership.xml","form_type":"4"}},{"id":1296138,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2025-01-23T16:05:07.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 48 substantially equal monthly installments beginning on February 1, 2025."}],"balance_after":90000,"derivative":{"exercise_price":2.57,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0000950170-25-008317","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017025008317/ownership.xml","form_type":"4"}},{"id":1427194,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":16234,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":16234,"derivative":{"exercise_price":3.56,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":16234},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427193,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":26090,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024."}],"balance_after":26090,"derivative":{"exercise_price":3.56,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":26090},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427192,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":35897,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in 48 substantially equal monthly installments beginning on January 13, 2024."}],"balance_after":35897,"derivative":{"exercise_price":3.56,"expiration_date":"2033-12-12","underlying":"Common Stock","underlying_shares":35897},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427191,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":42051,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023."}],"balance_after":42051,"derivative":{"exercise_price":3.56,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":42051},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427190,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":10200,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in 48 substantially equal monthly installments beginning on January 13, 2023."}],"balance_after":10200,"derivative":{"exercise_price":3.56,"expiration_date":"2032-12-12","underlying":"Common Stock","underlying_shares":10200},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427189,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":29148,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 substantially equal monthly installments beginning on January 6, 2022."}],"balance_after":29148,"derivative":{"exercise_price":3.56,"expiration_date":"2031-12-05","underlying":"Common Stock","underlying_shares":29148},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427188,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":32051,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested as to 25% of the underlying shares on August 30, 2022, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter."}],"balance_after":32051,"derivative":{"exercise_price":3.56,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":32051},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427187,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16234,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":16234},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427186,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26090,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024."}],"balance_after":0,"derivative":{"exercise_price":8.19,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":26090},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427185,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35897,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in 48 substantially equal monthly installments beginning on January 13, 2024."}],"balance_after":0,"derivative":{"exercise_price":4.49,"expiration_date":"2033-12-12","underlying":"Common Stock","underlying_shares":35897},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427184,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":42051,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":42051},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427183,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in 48 substantially equal monthly installments beginning on January 13, 2023."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2032-12-12","underlying":"Common Stock","underlying_shares":10200},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427182,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":29148,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 substantially equal monthly installments beginning on January 6, 2022."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2031-12-05","underlying":"Common Stock","underlying_shares":29148},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427181,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32051,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested as to 25% of the underlying shares on August 30, 2022, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":32051},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1557386,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-03-29T16:30:17.000Z","date":"2024-03-27","kind":"grant","planned":false,"acquired":true,"shares":16234,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":16234,"derivative":{"exercise_price":16,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":16234},"source":{"system":"sec-edgar","filing":"0000950170-24-038699","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024038699/ownership.xml","form_type":"4"}},{"id":2756711,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2021-04-05T17:35:45.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":1177,"price":2.66,"value":3130.82,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs on 03/31/21. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."}],"balance_after":7764,"source":{"system":"sec-edgar","filing":"0001610618-21-000030","document":"wf-form4_161765846617206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000161061821000030/wf-form4_161765846617206.xml","form_type":"4"}},{"id":2756710,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2021-04-05T17:35:45.000Z","date":"2021-03-31","kind":"grant","acquired":true,"shares":2800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person was previously granted a performance restricted stock unit (PRSU) to vest upon the achievement of a certain milestone event that occurred on 3/31/21."}],"balance_after":8941,"source":{"system":"sec-edgar","filing":"0001610618-21-000030","document":"wf-form4_161765846617206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000161061821000030/wf-form4_161765846617206.xml","form_type":"4"}},{"id":2756709,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2021-04-05T17:35:45.000Z","date":"2021-01-05","kind":"sale","acquired":false,"shares":824,"price":2.06,"value":1697.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on 1/1/21. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."}],"balance_after":6141,"source":{"system":"sec-edgar","filing":"0001610618-21-000030","document":"wf-form4_161765846617206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000161061821000030/wf-form4_161765846617206.xml","form_type":"4"}},{"id":2777200,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-03-19T21:00:47.000Z","date":"2021-03-17","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 17, 2021."}],"balance_after":135000,"derivative":{"exercise_price":2.55,"expiration_date":"2031-03-16","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001610618-21-000018","document":"wf-form4_161620203129692.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000161061821000018/wf-form4_161620203129692.xml","form_type":"4"}},{"id":3197598,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-03-23T19:21:08.000Z","date":"2020-03-19","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 19, 2020."}],"balance_after":90000,"derivative":{"exercise_price":1.98,"expiration_date":"2030-03-18","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-20-020753","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919120020753/doc4.xml","form_type":"4"}},{"id":3317435,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2020-01-06T17:28:55.000Z","date":"2020-01-02","kind":"sale","acquired":false,"shares":834,"price":3.86,"value":3219.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on 12/31/19. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."}],"balance_after":6965,"source":{"system":"sec-edgar","filing":"0001209191-20-002038","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919120002038/doc4.xml","form_type":"4"}},{"id":3402581,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2019-10-01T17:07:22.000Z","date":"2019-09-27","kind":"sale","acquired":false,"shares":1001,"price":1.86,"value":1861.86,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on 9/12/19. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."}],"balance_after":7799,"source":{"system":"sec-edgar","filing":"0001209191-19-051327","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919119051327/doc4.xml","form_type":"4"}},{"id":3413518,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Restricted Stock Unit","published_at":"2019-09-16T17:28:41.000Z","date":"2019-09-12","kind":"exercise","acquired":false,"shares":2800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction relates to the vesting of shares upon the achievement of various clinical and corporate milestones that were previously reported in Table II of the Reporting Person's Form 4 filed 2/1/19."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"A portion of the shares vest upon the achievement of various clinical and corporate milestones."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"A portion of the shares vest upon the achievement of various clinical and corporate milestones."}],"balance_after":11200,"derivative":{"underlying":"Common Stock","underlying_shares":2800},"source":{"system":"sec-edgar","filing":"0001209191-19-049684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919119049684/doc4.xml","form_type":"4"}},{"id":3413517,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2019-09-16T17:28:41.000Z","date":"2019-09-12","kind":"grant","acquired":true,"shares":2800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction relates to the vesting of shares upon the achievement of various clinical and corporate milestones that were previously reported in Table II of the Reporting Person's Form 4 filed 2/1/19."}],"balance_after":8800,"source":{"system":"sec-edgar","filing":"0001209191-19-049684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919119049684/doc4.xml","form_type":"4"}},{"id":3580662,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-03-22T16:47:00.000Z","date":"2019-03-21","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 21, 2019."}],"balance_after":65000,"derivative":{"exercise_price":2.61,"expiration_date":"2029-03-20","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-19-021008","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919119021008/doc4.xml","form_type":"4"}},{"id":3679310,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Restricted Stock Unit","published_at":"2019-02-01T19:03:28.000Z","date":"2019-01-31","kind":"exercise","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares shall vest upon the achievement of various clinical and corporate milestones."}],"balance_after":14000,"derivative":{"expiration_date":"2022-01-01","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001209191-19-006609","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919119006609/doc4.xml","form_type":"4"}},{"id":3679309,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2019-02-01T19:03:28.000Z","date":"2019-01-31","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"1/3rd of the total number of shares subject to the restricted stock unit shall vest on each January 1 of 2020, 2021 and 2022."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001209191-19-006609","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919119006609/doc4.xml","form_type":"4"}}]}